Archives
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2018-07
-
br Results and discussion br Conclusion In summary starting
2021-11-26

Results and discussion Conclusion In summary, starting from our previous lead N-acetyl D-galactosamine receptor 1, we replaced the 5-nitropyrimidine core with pyrimidopyrimidine to obtain a series of novel compounds as drug candidates of GPR119 agonist for treatment of type 2 diabetes. Some de
-
Based on these findings we set out
2021-11-26

Based on these findings, we set out to identify GPR109A agonists capable of biasing the receptor's signaling towards the functional anti-lipolytic and presumed therapeutic response, and away from the flushing side-effect pathways. Indeed, using recombinantly expressed GPR109A, two classes of compoun
-
While NR upregulation in the spinal cord is known to
2021-11-25

While NR1 upregulation in the spinal cord is known to contribute to pathological pain [7], [22] and furthermore, NR1 expression in the spinal cord has been shown to be reduced by continuous administration of the GlyT1-inhibitor ALX5407 [23], little is known about possible expressional changes of NR1
-
br Materials and methods br
2021-11-25

Materials and methods Results and discussion Conclusion A new label-free targeted methodology using two-step fractionation coupled with conventional microflow LC-MS/MS was developed and validated to profile 54 selected clinically relevant human plasma glycoproteins. The developed method has
-
(±)-CPSI 1306 In conclusion we show to our knowledge fo
2021-11-25

In conclusion, we show, to our knowledge for the first-time, compelling evidence for functional OTR and GHSR crosstalk, which is likely via the formation of a novel OTR/GHSR heterocomplex with important downstream signalling consequences. This OTR/GHSR interaction is poised to play an important phys
-
During the course of the development of aminothiazole derive
2021-11-25

During the course of the development of aminothiazole-derived small molecule GSMs, SGSM-36 (Fig. 1A) was discovered and exhibited good activity for suppressing the production of Aβ42 (Aβ42 IC50=63nM) (Rynearson et al., 2016; Wagner et al., 2014). In addition, SGSM-36 exhibited improved physicochemic
-
PAI-039 mg As mentioned earlier two different isoforms of TF
2021-11-25

As mentioned earlier two different isoforms of TFE3 [16] have been reported viz. the full length (TFE3L) and smaller (TFE3S) without exon 1&2. TFE3S lacks an N-terminal acidic activation domain which is present in TFE3L hence is a dominant negative form of TFE3L [51]. This dominant negative feature
-
In this study we have investigated the expression of FXR
2021-11-25

In this study, we have investigated the expression of FXR and TGR5 in CCA tissues in two independent cohorts of patients and determined their association with tumor clinicopathological parameters. The expression of both BA receptors was also evaluated in CCA human cells and normal human cholangiocyt
-
As demonstrated by Bayliss Bayliss myogenic response is
2021-11-25

As demonstrated by Bayliss Bayliss, [22] myogenic response is the ability of the blood vessels to contract in response to intraluminal pressure elevation. This is intrinsic to VSMCs, particularly in small arteries (dimeter Ecdysterone mg polymerization within VSMCs in response to increased intravasc
-
br Results and discussion br Conclusions As described
2021-11-25

Results and discussion Conclusions As described above, the SAR study based on compound 1 led to the identification of compound 4 as an ideal inhibitor. An enzyme level investigation showed that 4 is a more potent and selective FGFRs tyrosine kinase inhibitor than is Ponatinib. In addition, the
-
The NGS of six Southern Brazil patients revealed three diffe
2021-11-25

The NGS of six Southern Brazil patients revealed three different variants: c.472C > T (p.Arg158Trp); c.958G>A (p.Gly320Arg) and c.986T>C (p.Leu329Pro) (Table 2). The amino acids involved in these substitutions were evolutionarily conserved in different species (Fig. 1B). The amino Spiperone hydrochl
-
The ETA receptor has a higher affinity for
2021-11-25

The ETA receptor has a higher affinity for endothelin-1 than the two other agonists, with an affinity order of endothelin-1>endothelin-2>endothelin-3, while the ETB receptor exhibits similar affinities for all three isopeptides (Arai et al., 1990b, Sakurai et al., 1990). Earlier studies of the selec
-
In a preliminary communication we showed that AT and ETB
2021-11-25

In a preliminary communication, we showed that AT and ETB receptors colocalize and coimmunoprecipitate in renal proximal tubule cells, and stimulation of the AT receptor increases ETB receptor expression in Wistar-Kyoto (WKY) rats [abstract; Zeng C,, 26:80A, 2003]. We hypothesize that the ETB recept
-
Some studies using RNAi have recently been invalidated
2021-11-25

Some studies using RNAi have recently been invalidated by CRISPR/Cas9 [25] due to significant off-target effects of RNAi [26]. In this study, we have used both RNAi and CRISPR/Cas9 techniques and have observed consistent and similar phenotypes thus; knockdown or knockout of PATZ1 resulted in reducti
-
GSK dimethylpiperidin yl butoxy phenyl piperidine carbonyl n
2021-11-25

GSK-835726 (3-[4-[4-[4-[4-(3,3-dimethylpiperidin-1-yl)butoxy]phenyl]piperidine-1-carbonyl]naphthalen-1-yl]propanoic acid) is a dual H1/H3 receptor antagonist with the potential to be used in allergic rhinitis. Likewise GSK-1004723, the drug-likeness criteria have not been passed by this drug candida
14587 records 527/973 page Previous Next First page 上5页 526527528529530 下5页 Last page